Meta-analysis of efficacy of zinc acexamate in peptic ulcer

E. Jiménez Villa; F. Bosch; J. L. Galmé; J. E. Baños

doi:10.1159/000200871

Meta-analysis of efficacy of zinc acexamate in peptic ulcer

E. Jiménez Villa, F. Bosch, J. L. Galmé, J. E. Baños

Research output: Contribution to journal › Article › Research › peer-review

9 Citations (Scopus)

Abstract

Zinc acexamate (ZAC) is a new drug for the treatment of peptic ulcer. The present study was performed in order to evaluate the clinical efficacy of ZAC in peptic ulcer, using a meta-analysis of all randomized clinical trials performed with this drug. Eighteen studies were reviewed, but only 13 were considered in the final analysis. The total number of patients was 757. Control groups included placebo or H<inf>2</inf> receptor antagonist drugs. Healing rate, assessed by endoscopy, was selected as the criterion for evaluating drug efficacy. The meta-analysis was performed using a modified version of the Mantel-Haenszel method. ZAC proved to be better than placebo in the treatment of peptic ulccr (pooled odds ratio: POR = 5.55; 95% confidence interval: 95% CI = 2.20-14.04) and not different from H<inf>2</inf> receptor antagonist drugs when compared in patients with gastric (POR -1.14; 95% CI = 0.47-2.72), duodenal (POR = 0.97; 95% CI = 0.13-7.33) or both ulcer types (POR = 1.10; 95% CI = 0.74-1.64). The present results show that ZAC is an effective drug for the treatment of peptic ulcer. © 1992 S. Karger AG, Basel.

Original language	English
Pages (from-to)	18-26
Journal	Digestion
Volume	51
Issue number	1
DOIs	https://doi.org/10.1159/000200871
Publication status	Published - 1 Jan 1992

Keywords

Clinical trials
Meta-analysis
Peptic ulcer
Zinc acexamate

Access to Document

10.1159/000200871

Fingerprint Dive into the research topics of 'Meta-analysis of efficacy of zinc acexamate in peptic ulcer'. Together they form a unique fingerprint.

Cite this

@article{54ca0a2fd38e441f8beb89507d198c66,

title = "Meta-analysis of efficacy of zinc acexamate in peptic ulcer",

abstract = "Zinc acexamate (ZAC) is a new drug for the treatment of peptic ulcer. The present study was performed in order to evaluate the clinical efficacy of ZAC in peptic ulcer, using a meta-analysis of all randomized clinical trials performed with this drug. Eighteen studies were reviewed, but only 13 were considered in the final analysis. The total number of patients was 757. Control groups included placebo or H2 receptor antagonist drugs. Healing rate, assessed by endoscopy, was selected as the criterion for evaluating drug efficacy. The meta-analysis was performed using a modified version of the Mantel-Haenszel method. ZAC proved to be better than placebo in the treatment of peptic ulccr (pooled odds ratio: POR = 5.55; 95% confidence interval: 95% CI = 2.20-14.04) and not different from H2 receptor antagonist drugs when compared in patients with gastric (POR -1.14; 95% CI = 0.47-2.72), duodenal (POR = 0.97; 95% CI = 0.13-7.33) or both ulcer types (POR = 1.10; 95% CI = 0.74-1.64). The present results show that ZAC is an effective drug for the treatment of peptic ulcer. {\textcopyright} 1992 S. Karger AG, Basel.",

keywords = "Clinical trials, Meta-analysis, Peptic ulcer, Zinc acexamate",

author = "{Jim{\'e}nez Villa}, E. and F. Bosch and Galm{\'e}, {J. L.} and Ba{\~n}os, {J. E.}",

year = "1992",

month = jan,

day = "1",

doi = "10.1159/000200871",

language = "English",

volume = "51",

pages = "18--26",

journal = "Digestion",

issn = "0012-2823",

number = "1",

}

TY - JOUR

T1 - Meta-analysis of efficacy of zinc acexamate in peptic ulcer

AU - Jiménez Villa, E.

AU - Bosch, F.

AU - Galmé, J. L.

AU - Baños, J. E.

PY - 1992/1/1

Y1 - 1992/1/1

N2 - Zinc acexamate (ZAC) is a new drug for the treatment of peptic ulcer. The present study was performed in order to evaluate the clinical efficacy of ZAC in peptic ulcer, using a meta-analysis of all randomized clinical trials performed with this drug. Eighteen studies were reviewed, but only 13 were considered in the final analysis. The total number of patients was 757. Control groups included placebo or H2 receptor antagonist drugs. Healing rate, assessed by endoscopy, was selected as the criterion for evaluating drug efficacy. The meta-analysis was performed using a modified version of the Mantel-Haenszel method. ZAC proved to be better than placebo in the treatment of peptic ulccr (pooled odds ratio: POR = 5.55; 95% confidence interval: 95% CI = 2.20-14.04) and not different from H2 receptor antagonist drugs when compared in patients with gastric (POR -1.14; 95% CI = 0.47-2.72), duodenal (POR = 0.97; 95% CI = 0.13-7.33) or both ulcer types (POR = 1.10; 95% CI = 0.74-1.64). The present results show that ZAC is an effective drug for the treatment of peptic ulcer. © 1992 S. Karger AG, Basel.

AB - Zinc acexamate (ZAC) is a new drug for the treatment of peptic ulcer. The present study was performed in order to evaluate the clinical efficacy of ZAC in peptic ulcer, using a meta-analysis of all randomized clinical trials performed with this drug. Eighteen studies were reviewed, but only 13 were considered in the final analysis. The total number of patients was 757. Control groups included placebo or H2 receptor antagonist drugs. Healing rate, assessed by endoscopy, was selected as the criterion for evaluating drug efficacy. The meta-analysis was performed using a modified version of the Mantel-Haenszel method. ZAC proved to be better than placebo in the treatment of peptic ulccr (pooled odds ratio: POR = 5.55; 95% confidence interval: 95% CI = 2.20-14.04) and not different from H2 receptor antagonist drugs when compared in patients with gastric (POR -1.14; 95% CI = 0.47-2.72), duodenal (POR = 0.97; 95% CI = 0.13-7.33) or both ulcer types (POR = 1.10; 95% CI = 0.74-1.64). The present results show that ZAC is an effective drug for the treatment of peptic ulcer. © 1992 S. Karger AG, Basel.

KW - Clinical trials

KW - Meta-analysis

KW - Peptic ulcer

KW - Zinc acexamate

U2 - 10.1159/000200871

DO - 10.1159/000200871

M3 - Article

VL - 51

SP - 18

EP - 26

JO - Digestion

JF - Digestion

SN - 0012-2823

IS - 1

ER -